EML4 and cancer: In addition, the study did not find the mutation status in 261 other malignant tumor samples tested for EML4-ALK fusion, which also indicated that EML4-ALK was a highly specific mutation of NSCLC, and this also provided a basis for specific therapy for NSCLC patients with ALK mutations (3).